Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts. Lidorestat can be used to treat complications of chronic diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $40 | In Stock | |
10 mg | $64 | In Stock | |
25 mg | $108 | In Stock | |
50 mg | $165 | In Stock | |
1 mL x 10 mM (in DMSO) | $45 | In Stock |
Description | Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts. Lidorestat can be used to treat complications of chronic diabetes. |
Targets&IC50 | Rldose reductase:5 nM |
In vitro | Lidorestat's reported IC50 value for recombinant human aldose reductase (/h/-ALR2) in in vitro experiments is 5 μM. against recombinant human aldehyde reductase (/h/-ALR1), the selectivity ratio of /h/-ALR1 to /h/-ALR2 is 5400:1 [1,2]. |
In vivo | Lidorestat (25 mg/kg/day, oral administration, twice daily for 6 weeks) reduces fructose levels and lowers mortality rates in diabetic, hAR-expressing mice without affecting weight.[1] |
Alias | IDD-676 |
Molecular Weight | 376.35 |
Formula | C18H11F3N2O2S |
Cas No. | 245116-90-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (132.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.